Cytokine Therapy for Cancer

Surgical Oncology Clinics of North America

Volumn 16, Issue 4, 2007, Pages 793-818

  Kim Schulze, Seunghee ^a   Taback, Bret ^a   Kaufman, Howard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; FLUDARABINE; FLUOROURACIL; GAMMA INTERFERON; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; MEDROXYPROGESTERONE;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNITY; BLOOD CLOTTING DISORDER; CANCER; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RESEARCH; CAPILLARY LEAK SYNDROME; CHILL; CHOLESTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISORIENTATION; DRUG BINDING; DRUG RESPONSE; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG EDEMA; LUPUS VULGARIS; MANIA; MELANOMA; MYALGIA; MYOCARDITIS; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TUMOR IMMUNITY; VISUAL HALLUCINATION; VITILIGO; VOMITING;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, CYTOKINE;

EID: 36148973553     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.07.011     Document Type: Review

References (217)

1. Kaplan D.H., Shankaran V., Dighe A.S., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95 (1998) 7556-7561
2. Picaud S., Bardot B., De Maeyer E., et al. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 22 (2002) 457-462
3. Shankaran V., Ikeda H., Bruce A.T., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
4. Pure E., Allison J.P., and Schreiber R.D. Breaking down the barriers to cancer immunotherapy. Nat Immun 6 (2005) 1207-1210
5. Petrulio C.A., Kim-Schulze S., and Kaufman H.L. The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther 6 (2006) 671-684
6. Malek T.R., Yu A., Vincek V., et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2R[beta]-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17 (2002) 167-178
7. Abbas A.K., Lichtman A.H., and Pober P.S. Cellular and molecular immunology. 5th edition (2003), Saunders, Philadelphia
8. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 (2007) 1167-1174
9. Jonuleit H., Schmitt E., Stassen M., et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 193 (2001) 1285-1294
10. Asseman C., Mauze S., Leach M.W., et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190 (1999) 995-1004
11. Setoguchi R., Hori S., Takahashi T., et al. Homeostatic maintenance of natural FOXP3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201 (2005) 723-735
12. Waldmann T.A. The interleukin-2 receptor on normal and malignant lymphocytes. Adv Exp Med Biol 213 (1987) 129-137
13. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006) 595-601
14. Chan W.C., Dahl C., Waldmann T., et al. Large granular lymphocyte proliferation: an analysis of T-cell receptor gene arrangement and expression and the effect of in vitro culture with inducing agents. Blood 71 (1988) 52-58
15. Begley C.G., Burton J.D., Tsudo M., et al. Human B lymphocytes express the p75 component of the interleukin 2 receptor. Leuk Res 14 (1990) 263-271
16. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 (2000) 455
17. Golgher D., Jones E., Powrie F., et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32 (2002) 3267-3275
18. Thornton A.M., Donovan E.E., Piccirillo C.A., et al. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172 (2004) 6519-6523
19. Shevach E.M., Piccirillo C.A., Thornton A.M., et al. Control of T cell activation by CD4+CD25+ suppressor T cells. Novartis Found Symp 252 (2003) 24-36 [discussion: 36-44, 106-14]
20. McHugh R.S., Shevach E.M., and Thornton A.M. Control of organ-specific autoimmunity by immunoregulatory CD4(+)CD25(+) T cells. Microbes Infect 3 (2001) 919-927
21. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287-296
22. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202 (2004) 8-32
23. Constantinescu S.N., Croze E., Wang C., et al. Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex. Proc Natl Acad Sci U S A 91 (1994) 9602-9606
24. Muller U., Steinhoff U., Reis L.F., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 (1994) 1918-1921
25. Muller M., Ibelgaufts H., and Kerr I.M. Interferon response pathways-a paradigm for cytokine signalling?. J Viral Hepat 1 (1994) 87-103
26. Isaacs A., and Lindenmann J. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957. J Interferon Res 7 (1987) 429-438
27. Basham T.Y., Bourgeade M.F., Creasey A.A., et al. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci U S A 79 (1982) 3265-3269
28. Dolei A., Capobianchi M.R., and Ameglio F. Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta. Infect Immun 40 (1983) 172-176
29. Ameglio F., Capobianchi M.R., Dolei A., et al. Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC loci. Infect Immun 42 (1983) 122-125
30. Jones C.M., Varesio L., Herberman R.B., et al. Interferon activates macrophages to produce plasminogen activator. J Interferon Res 2 (1982) 377-386
31. Herberman R.B. Overview on NK cells and possible mechanisms for their cytotoxic activity. Adv Exp Med Biol 146 (1982) 337-351
32. Herberman R.B. Overview and perspectives: natural resistance mechanisms. Adv Exp Med Biol 155 (1982) 799-808
33. Brunda M.J., Varesio L., Herberman R.B., et al. Interferon-independent, lectin-induced augmentation of murine natural killer cell activity. Int J Cancer 29 (1982) 299-307
34. Wagner T.C., Velichko S., Chesney S.K., et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 111 (2004) 32-42
35. Tsuruoka N., Sugiyama M., Tawaragi Y., et al. Inhibition of in vitro angiogenesis by lymphotoxin and interferon-gamma. Biochem Biophys Res Commun 155 (1988) 429-435
36. Dunn G.P., Ikeda H., Bruce A.T., et al. Interferon-gamma and cancer immunoediting. Immunol Res 32 (2005) 231-245
37. Dunn G.P., Bruce A.T., Sheehan K.C., et al. A critical function for type I interferons in cancer immunoediting. Nat Immun 6 (2005) 722-729
38. Carnaud C., Lee D., Donnars O., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163 (1999) 4647-4650
39. Lighvani A.A., Frucht D.M., Jankovic D., et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A 98 (2001) 15137-15142
40. Frucht D.M., Fukao T., Bogdan C., et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 22 (2001) 556-560
41. Boehm U., Klamp T., Groot M., et al. Cellular responses to interferon-gamma. Annu Rev Immunol 15 (1997) 749-795
42. Freedman A.S., Freeman G.J., Rhynhart K., et al. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 137 (1991) 429-437
43. Yong V.W., Moumdjian R., Yong F.P., et al. Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proc Natl Acad Sci U S A 88 (1991) 7016-7020
44. Groettrup M., van den Broek M., Schwarz K., et al. Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 21 (2001) 339-358
45. Groettrup M., Khan S., Schwarz K., et al. Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why?. Biochimie 83 (2001) 367-372
46. Snapper C.M., and Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236 (1987) 944-947
47. Street S.E., Trapani J.A., MacGregor D., et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196 (2002) 129-134
48. Coughlin C.M., Salhany K.E., Gee M.S., et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998) 25-34
49. Coughlin C.M., Salhany K.E., Wysocka M., et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101 (1998) 1441-1452
50. Friesel R., Komoriya A., and Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 104 (1987) 689-696
51. Elhilali M.M., Gleave M., Fradet Y., et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 86 (2000) 613-618
52. Koziner B., Dengra C., Cisneros M., et al. Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation. Acta Haematol 108 (2002) 66-73
53. Barnetson R.S., and Halliday G.M. Regression in skin tumours: a common phenomenon. Australas J Dermatol 38 Suppl 1 (1997) S63-S65
54. Panagopoulos E., and Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol 23 (1983) 8-10
55. Gromet M.A., Epstein W.L., and Blois M.S. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 42 (1978) 2282-2292
56. Dudley M.E., Wunderlich J., Nishimura M.I., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (1997) 24 (2001) 363-373
57. Atkins M.B., Regan M., and McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10 (2004) 6342S-6346S
58. Atkins M.B. Interleukin-2: clinical applications. Semin Oncol 29 (2002) 12-17
59. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
60. Schwartz R., Stover L., and Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology 16 (2002) 11-20
61. Klempner M.S., Noring R., Mier J.W., et al. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322 (1990) 959-965
62. Rosenberg S.A., Zhai Y., Yang J.C., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90 (1998) 1894-1900
63. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163 (1999) 1690-1695
64. Gollob J.A., Upton M.P., DeWolf W.C., et al. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 58 (2001) 1058
65. Sparano J.A., Fisher R.I., Sunderland M., et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11 (1993) 1969-1977
66. Feun L., Marini A., Moffat F., et al. Cyclosporine A, alpha-l interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. Cancer Invest 23 (2005) 3-8
67. Atkins M.B., Gollob J.A., Sosman J.A., et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 8 (2002) 3075-3081
68. McDermott D.F., Regan M.M., and Atkins M.B. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer 5 (2006) 114-119
69. Gollob J.A., Veenstra K.G., Parker R.A., et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21 (2003) 2564-2573
70. Eton O., Rosenblum M.G., Legha S.S., et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 95 (2002) 127-134
71. Hauschild A., and Kleeberg U.R. Adjuvant therapy of melanoma. From non-specific immune stimulants into the future. Hautarzt 57 (2006) 764-772
72. Hauschild A., Volkenandt M., and Garbe C. Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries. Dtsch Med Wochenschr 125 (2000) 1272-1278
73. Khor M., Lowrie D.B., Coates A.R., et al. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol 67 (1986) 587-596
74. Hersey P., MacDonald M., Hall C., et al. Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer 57 (1986) 1666-1674
75. Coates A., Rallings M., Hersey P., et al. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 6 (1986) 1-4
76. Neefe J.R., Legha S.S., Markowitz A., et al. Phase II study of recombinant alpha-interferon in malignant melanoma. Am J Clin Oncol 13 (1990) 472-476
77. Vlock D.R., Andersen J., Kalish L.A., et al. Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 19 (1996) 433-442
78. Sparano J.A., Lipsitz S., Wadler S., et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol 19 (1996) 546-551
79. Schiller J.H., Pugh M., Kirkwood J.M., et al. Eastern Cooperative Group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2 (1996) 29-36
80. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
81. Franke W., Neumann N.J., Ruzicka T., et al. Adjuvant therapy of malignant melanoma. Schweiz Rundsch Med Prax 90 (2001) 301-306
82. Cole B.F., Gelber R.D., Kirkwood J.M., et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 14 (1996) 2666-2673
83. Agarwala S.S., and Kirkwood J.M. Interferons in melanoma. Curr Opin Oncol 8 (1996) 167-174
84. Santhanam S., Decatris M., and O'Byrne K. Potential of interferon-alpha in solid tumours: part 2. BioDrugs 16 (2002) 349-372
85. Decatris M., Santhanam S., and O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs 16 (2002) 261-281
86. Falkson C.I., Ibrahim J., Kirkwood J.M., et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16 (1998) 1743-1751
87. Kirkwood J.M., Manola J., Ibrahim J., et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10 (2004) 1670-1677
88. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
89. Jonasch E., Kumar U.N., Linette G.P., et al. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 6 (2000) 139-145
90. Jonasch E., and Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6 (2001) 34-55
91. Greenberg D.B., Jonasch E., Gadd M.A., et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 89 (2000) 356-362
92. Musselman D.L., Lawson D.H., Gumnick J.F., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344 (2001) 961-966
93. Jones T.H., Wadler S., and Hupart K.H. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 25 (1998) 54-63
94. Brenard R. Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg 60 (1997) 211-213
95. Dalekos G.N., Christodoulou D., Kistis K.G., et al. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 10 (1998) 933-939
96. Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709-718
97. Aragane Y., Riemann H., Bhardwaj R.S., et al. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol 153 (1994) 5366-5372
98. Aste-Amezaga M., D'Andrea A., Kubin M., et al. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 156 (1994) 480-492
99. Kubin M., Chow J.M., and Trinchieri G. Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 83 (1994) 1847-1855
100. Perussia B., Chan S.H., D'Andrea A., et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol 149 (1992) 3495-3502
101. Chehimi J., Starr S.E., Frank I., et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 175 (1992) 789-796
102. Chan S.H., Kobayashi M., Santoli D., et al. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 148 (1992) 92-98
103. Rao J.B., Chamberlain R.S., Bronte V., et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 156 (1996) 3357-3365
104. Strengell M., Lehtonen A., Matikainen S., et al. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol 79 (2006) 1279-1285
105. Li Q., Carr A.L., Donald E.J., et al. Synergistic effects of IL-12 and IL-18 in skewing rumor-reactive T-cell responses towards a type 1 pattern. Cancer Res 65 (2005) 1063-1070
106. Kaufman H.L., Flanagan K., Lee C.S., et al. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 20 (2002) 1862-1869
107. Yoshimoto T., Takeda K., Tanaka T., et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 161 (1998) 3400-3407
108. Yoshimoto T., Nagai N., Ohkusu K., et al. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta+ T cells. J Immunol 161 (1998) 1483-1492
109. Smyth M.J., Swann J., Kelly J.M., et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 200 (2004) 1325-1335
110. Kawamura T., Takeda K., Mendiratta S.K., et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160 (1998) 16-19
111. Boggio K., Nicoletti G., Di Carlo E., et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188 (1998) 589-596
112. Mahvi D.M., Henry M.B., Albertini M.R., et al. Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial. Cancer Gene Ther (2007)
113. Gollob J.A., Mier J.W., Veenstra K., et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6 (2000) 1678-1692
114. Prlic M., Blazar B.R., Farrar M.A., et al. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 197 (2003) 967-976
115. Waldmann T.A., and Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annual Review of Immunology 17 (1999) 19-49
116. Marks-Konczalik J., Dubois S., Losi J.M., et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 97 (2000) 11445-11450
117. Ku C.C., Murakami M., Sakamoto A., et al. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288 (2000) 675-678
118. Waldmann T.A. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends in Molecular Medicine 9 (2003) 517-521
119. Meresse B., Chen Z., Ciszewski C., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21 (2004) 357-366
120. Zaft T., Sapoznikov A., Krauthgamer R., et al. CD11high dendritic cell ablation impairs lymphopenia-driven proliferation of naive and memory CD8+ T cells. J Immunol 175 (2005) 6428-6435
121. Di Carlo E., Comes A., Basso S., et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 165 (2000) 3111-3118
122. Okamura H., Tsutsi H., Komatsu T., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 (1995) 88-91
123. Tsutsui H., Matsui K., Kawada N., et al. IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 159 (1997) 3961-3967
124. Tomura M., Zhou X.Y., Maruo S., et al. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. J Immunol 160 (1998) 4738-4746
125. Tomura M., Maruo S., Mu J., et al. Differential capacities of CD4+ CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J Immunol 160 (1998) 3759-3765
126. Takeda K., Tsutsui H., Yoshimoto T., et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8 (1998) 383-390
127. Okamura H., Tsutsui H., Kashiwamura S., et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70 (1998) 281-312
128. Okamura H., Kashiwamura S., Tsutsui H., et al. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 10 (1998) 259-264
129. Robertson M.J., Mier J.W., Logan T., et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 12 (2006) 4265-4273
130. Park C.C., Morel J.C., Amin M.A., et al. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167 (2001) 1644-1653
131. Morel J.C., Park C.C., Woods J.M., et al. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biolumin Chemilumin 276 (2001) 37069-37075
132. Morel J.C., Park C.C., Kumar P., et al. Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 81 (2001) 1371-1383
133. Kaser A., Novick D., Rubinstein M., et al. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 129 (2002) 332-338
134. Amin M.A., Mansfield P.J., Pakozdi A., et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 56 (2007) 1787-1797
135. Lee J.K., Kim S.H., Lewis E.C., et al. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A 101 (2004) 8815-8820
136. Parrish-Novak J., Dillon S.R., Nelson A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
137. Brandt K., Bulfone-Paus S., Jenckel A., et al. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol 121 (2003) 1379-1382
138. Brandt K., Bulfone-Paus S., Foster D.C., et al. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102 (2003) 4090-4098
139. Suto A., Nakajima H., Hirose K., et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 100 (2002) 4565-4573
140. Pene J., Guglielmi L., Gauchat J.F., et al. IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene. J Immunol 177 (2006) 5006-5013
141. Jin H., and Malek T.R. Redundant and unique regulation of activated mouse B lymphocytes by IL-4 and IL-21. J Leukoc Biol 80 (2006) 1416-1423
142. Furukawa J., Hara I., Nagai H., et al. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 176 (2006) 1198-1203
143. Cappuccio A., Elishmereni M., and Agur Z. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 66 (2006) 7293-7300
144. He H., Wisner P., Yang G., et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 4 (2006) 24-40
145. Smyth M.J., Hayakawa Y., Cretney E., et al. IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J Immunol 176 (2006) 6347-6355
146. Caven T.H., Shelburne A., Sato J., et al. IL-21 dependent IgE production in human and mouse in vitro culture systems is cell density and cell division dependent and is augmented by IL-10. Cell Immunol 238 (2005) 123-134
147. Burgess S.J., Marusina A.I., Pathmanathan I., et al. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 176 (2006) 1490-1497
148. Ettinger R., Sims G.P., Fairhurst A.M., et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 175 (2005) 7867-7879
149. Perez S.A., Mahaira L.G., Sotiropoulou P.A., et al. Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 18 (2006) 49-58
150. Li Y., Bleakley M., and Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175 (2005) 2261-2269
151. Takaki R., Hayakawa Y., Nelson A., et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 175 (2005) 2167-2173
152. Wood N., Bourque K., Donaldson D.D., et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol 231 (2004) 133-145
153. Mehta D.S., Wurster A.L., and Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol Rev 202 (2004) 84-95
154. Moroz A., Eppolito C., Li Q., et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173 (2004) 900-909
155. Strengell M., Julkunen I., and Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 76 (2004) 416-422
156. Pene J., Gauchat J.F., Lecart S., et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol 172 (2004) 5154-5157
157. Habib T., Nelson A., and Kaushansky K. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 112 (2003) 1033-1045
158. Collins M., Whitters M.J., and Young D.A. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res 28 (2003) 131-140
159. Curti B.D. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev Anticancer Ther 6 (2006) 905-909
160. Wang G., Tschoi M., Spolski R., et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63 (2003) 9016-9022
161. Kishida T., Asada H., Itokawa Y., et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 8 (2003) 552-558
162. Overwijk W.W., de Visser K.E., Tirion F.H., et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 176 (2006) 5213-5222
163. Langowski J.L., Zhang X., Wu L., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
164. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
165. Grabstein K.H., Urdal D.L., Tushinski R.J., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232 (1986) 506-508
166. Grabstein K., Mochizuki D., Kronheim S., et al. Regulation of antibody production in vitro by granulocyte-macrophage colony stimulating factor. J Mol Cell Immunol 2 (1986) 199-207
167. Leverkus M., Walczak H., McLellan A., et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood 96 (2000) 2628-2631
168. Hu X., and Zuckerman K.S. Cloning and sequencing of an alternative splicing-derived cDNA variant of the GM-CSF receptor alpha subunit, which encodes a truncated protein. Am J Hematol 58 (1998) 145-147
169. Jinushi M., Nakazaki Y., Dougan M., et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest 117 (2007) 1902-1913
170. Ridolfi L., Ridolfi R., Ascari-Raccagni A., et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 15 (2001) 218-223
171. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 22 (2003) 3188-3192
172. Spitler L.E., Grossbard M.L., Ernstoff M.S., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18 (2000) 1614-1621
173. O'Day S.J., Boasberg P.D., Piro L., et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8 (2002) 2775-2781
174. Britten C.D., Kabbinavar F., Randolph Hecht J., et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol (2007) [epub ahead of print]
175. McKeage K., and Wagstaff A.J. Sorafenib: in advanced renal cancer. Drugs 67 (2007) 475-483 [discussion: 484-5]
176. Rini B.I., Shaw V., Rosenberg J.E., et al. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5 (2006) 232-234
177. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
178. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
179. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 Suppl 1 (2000) S55-S57
180. Kirkwood J.M., Harris J.E., Vera R., et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 45 (1985) 863-871
181. Amato R. Modest effect of interferon alfa on metastatic renal-cell carcinoma. Lancet 353 (1999) 6-7
182. Flanigan R.C., and Yonover P.M. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol 19 (2001) 98-102
183. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
184. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 (2005) 843-846
185. Atzpodien J., Korfer A., Palmer P.A., et al. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha. Ann Oncol 1 (1990) 377-378
186. McDermott D.F., and Atkins M.B. Interleukin-2 therapy of metastatic renal cell carcinoma-predictors of response. Semin Oncol 33 (2006) 583-587
187. Golomb H.M., Jacobs A., Fefer A., et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 4 (1986) 900-905
188. Quesada J.R., and Gutterman J.U. Alpha interferons in B-cell neoplasms. Br J Haematol 64 (1986) 639-646
189. Golomb H.M., Ratain M.J., Mick R., et al. The treatment of hairy cell leukemia: an update. Leukemia 6 Suppl 2 (1992) 24-27
190. Goodman G.R., Burian C., Koziol J.A., et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21 (2003) 891-896
191. Talpaz M., McCredie K., Kantarjian H., et al. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 64 (1986) 87-95
192. Hehlmann R., Kister P., Willer A., et al. Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group. Leukemia 8 Suppl 1 (1994) S127-S132
193. Yasukawa M., Ohminami H., Kaneko S., et al. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 92 (1998) 3355-3361
194. Foon K.A., Sherwin S.A., Abrams P.G., et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 311 (1984) 1148-1152
195. Rohatiner A.Z., Gregory W.M., Peterson B., et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23 (2005) 2215-2223
196. Schalling M., Ekman M., Kaaya E.E., et al. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med 1 (1995) 707-708
197. Ezekowitz A., Mulliken J., and Folkman J. Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 79 Suppl 1 (1991) 67-68
198. Real F.X., Oettgen H.F., and Krown S.E. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4 (1986) 544-551
199. Mauss S., and Jablonowski H. Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995) 157-162
200. Wang H.Y., and Wang R.F. Regulatory T cells and cancer. Curr Opin Immunol 19 (2007) 217-223
201. Cesana G.C., DeRaffele G., Cohen S., et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 (2006) 1169-1177
202. Ahmadzadeh M., and Rosenberg S.A. IL-2 administration increases CD4+CD25(hi)FoxP3+ T cells in cancer patients. Blood 107 (2006) 2409-2414
203. Petrulio C.A., and Kaufman H.L. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 5 (2006) 9-19
204. Piancatelli D., Romano P., Sebastiani P., et al. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother (1997) 22 (1999) 25-32
205. Nemunaitis J., Khuri F., Ganly I., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19 (2001) 289-298
206. Weber W.P., Feder-Mengus C., Chiarugi A., et al. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol 36 (2006) 296-304
207. Gaspari P., Banerjee T., Malachowski W.P., et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 49 (2006) 684-692
208. Basu G.D., Tinder T.L., Bradley J.M., et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177 (2006) 2391-2402
209. Barnett B., Kryczek I., Cheng P., et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369-377
210. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
211. Dudley M.E., Wunderlich J.R., Yang J.C., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25 (2002) 243-251
212. Thompson R.H., Allison J.P., and Kwon E.D. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 24 (2006) 442-447
213. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100 (2003) 4712-4717
214. Egen J.G., Kuhns M.S., and Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immun 3 (2002) 611-618
215. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23 (2005) 8968-8977
216. Parmiani G., Castelli C., Pilla L., et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18 (2007) 226-232
217. Chakraborty M., Abrams S.I., Coleman C.N., et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64 (2004) 4328-4337